JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.
J Manag Care Spec Pharm
; 28(1): 108-114, 2022 Jan.
Article
em En
| MEDLINE
| ID: mdl-34949111
ABSTRACT
DISCLOSURES Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Sun Life Financial, uniQure, and United Healthcare. Agboola, Herron-Smith, Nhan, Rind, and Pearson are employed by ICER. Through their affiliated institutions, Atlas, Brouwer, Carlson, and Hansen received funding from ICER for the work described in this summary.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dermatite Atópica
/
Inibidores de Janus Quinases
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article